JN Watch the video to learn how APS reaches out to developing nations.
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


J Neurophysiol 90: 2875-2883, 2003. First published August 13, 2003; doi:10.1152/jn.00040.2003
0022-3077/03 $5.00
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
90/5/2875    most recent
00040.2003v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via ISI Web of Science (1)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Zhang, D. X.
Right arrow Articles by Bertram, E. H.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Zhang, D. X.
Right arrow Articles by Bertram, E. H.

Different Reactions of Control and Epileptic Rats to Administration of APV or Muscimol on Thalamic or CA3-Induced CA1 Responses

De Xing Zhang and E. H. Bertram

Department of Neurology, University of Virginia Health Sciences Center, Charlottesville, Virginia 22908

Submitted 15 January 2003; accepted in final form 25 July 2003

The physiology and pharmacology of CA1 is changed in epilepsy. There is evidence that the thalamic input to CA1 has a somewhat different physiological effect compared with the CA3 input. In this study we sought to determine whether this difference in physiology persists in epilepsy, and whether there are changes in the pharmacologic profile of these responses. Under urethane two stimulating electrodes were placed in mid to ventral CA3 and in the midline thalamus of control or epileptic rats. One glass micropipette electrode was placed into CA1 for recording. After the baseline acquisition of CA1-evoked responses to single- or paired-pulse stimulation, the stimuli were repeated with local application of either the GABAA agonist muscimol or the NMDA antagonist DL-2-amino-5-phosphonovalerate (APV). The CA1 response of epileptic rats had a smaller population postsynaptic potential (PSP) and spike amplitudes, longer PSP duration, multiple spikes, and the paired-pulse (at 20-ms intervals) facilitation in contrast to the paired-pulse depression seen in control and kindled rats. The duration of the PSP as well as the amplitude and number of spikes were reduced by administration of APV or muscimol into CA1 in both control and epileptic rats. In control rats, APV enhanced the depression induced by maximal paired thalamic or CA3 stimulation at 20-ms intervals and reduced the facilitation of threshold stimulation into no change. In contrast, muscimol in control rats reversed the depression induced by paired maximal stimulation into a mild facilitation and reduced the facilitation of threshold stimulation. In epileptic rats neither APV nor muscimol had a significant effect on the changes of the CA1 responses induced by maximal or threshold paired stimulation. This initial in vivo study demonstrated that the physiology and pharmacology of CA1 in epileptic rats are different from control rats. Although there are physiological differences in the evoked responses that are linked to the site of stimulation in the control and epileptic group, the pharmacology in each condition is independent of the site of stimulation.


Address for reprint requests and other correspondence: E. H. Bertram (E-mail: ehb2z{at}virginia.edu).







HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Visit Other APS Journals Online
Copyright © 2003 by the The American Physiological Society.